High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

被引:336
作者
Carrasco, DR
Tonon, G
Huang, YS
Zhang, YY
Sinha, R
Bin, F
Stewart, JP
Zhan, FG
Khatry, D
Protopopova, M
Protopopov, A
Sukhdeo, K
Hanamura, I
Stephens, O
Barlogie, B
Anderson, KC
Chin, L
Shaughnessy, JD
Brennan, C
DePinho, RA [1 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[3] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Donna & Donald Lambert Lab Myeloma Genet, Little Rock, AR 72205 USA
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Appl Canc Sci,Belfer Inst Innovat Canc Sci, Boston, MA 02115 USA
[5] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Dept Neurosurg, Neurosurg Serv, New York, NY 10021 USA
[6] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA
关键词
D O I
10.1016/j.ccr.2006.03.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To identify genetic events underlying the genesis and progression of multiple myeloma (MM), we conducted a high-resolution analysis of recurrent copy number alterations (CNAs) and expression profiles in a collection of MM cell lines and outcome-annotated clinical specimens. Attesting to the molecular heterogeneity of MM, unsupervised classification using non-negative matrix factorization (NMF) designed for array comparative genomic hybridization (aCGH) analysis uncovered distinct genomic subtypes. Additionally, we defined 87 discrete minimal common regions (MCRs) within recurrent and highly focal CNAs. Further integration with expression data generated a refined list of MM gene candidates residing within these MCRs, thereby providing a genomic framework for dissection of disease pathogenesis, improved clinical management, and initiation of targeted drug discovery for specific MM patients.
引用
收藏
页码:313 / 325
页数:13
相关论文
共 53 条
  • [1] Do human RNA helicases have a role in cancer?
    Abdelhaleem, M
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2004, 1704 (01): : 37 - 46
  • [2] High-resolution characterization of the pancreatic adenocarcinoma genome
    Aguirre, AJ
    Brennan, C
    Bailey, G
    Sinha, R
    Feng, B
    Leo, C
    Zhang, YY
    Zhang, J
    Gans, JD
    Bardeesy, N
    Cauwels, C
    Cordon-Cardo, C
    Redston, MS
    DePinho, RA
    Chin, L
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (24) : 9067 - 9072
  • [3] AvetLoiseau H, 1997, GENE CHROMOSOME CANC, V19, P124, DOI 10.1002/(SICI)1098-2264(199706)19:2<124::AID-GCC8>3.0.CO
  • [4] 2-0
  • [5] Treatment of multiple myeloma
    Barlogie, B
    Shaughnessy, J
    Tricot, G
    Jacobson, J
    Zangari, M
    Anaissie, E
    Walker, R
    Crowley, J
    [J]. BLOOD, 2004, 103 (01) : 20 - 32
  • [6] Thalidomide and hematopoietic-cell transplantation for multiple myeloma
    Barlogie, B
    Tricot, G
    Anaissie, E
    Shaughnessy, J
    Rasmussen, E
    van Rhee, F
    Fassas, A
    Zangari, M
    Hollmig, K
    Pineda-Roman, M
    Lee, C
    Talamo, G
    Thertulien, R
    Kiwan, E
    Krishna, S
    Fox, M
    Crowley, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) : 1021 - 1030
  • [7] Molecular pathogenesis and a consequent classification of multiple myeloma
    Bergsagel, PL
    Kuehl, WM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) : 6333 - 6338
  • [8] Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
    Bergsagel, PL
    Kuehl, WM
    Zhan, FH
    Sawyer, J
    Barlogie, B
    Shaughnessy, J
    [J]. BLOOD, 2005, 106 (01) : 296 - 303
  • [9] Chromosome translocations in multiple myeloma
    Bergsagel, PL
    Kuehl, WM
    [J]. ONCOGENE, 2001, 20 (40) : 5611 - 5622
  • [10] High-resolution global profiling of genomic alterations with long oligonucleotide microarray
    Brennan, C
    Zhang, YY
    Leo, C
    Feng, B
    Cauwels, C
    Aguirre, AJ
    Kim, MJ
    Protopopov, A
    Chin, L
    [J]. CANCER RESEARCH, 2004, 64 (14) : 4744 - 4748